Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple Myeloma
November 28, 2022

Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.

Factors in Selecting First-Line Therapy for Patients With Advanced RCC
November 28, 2022

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

Advanced Renal Cell Carcinoma: An Evolving Treatment Armamentarium
November 28, 2022

Expert oncologists Matthew Campbell, MD, MS, and Brian Rini, MD, open their discussion on advanced renal cell carcinoma management by defining cornerstone treatment approaches.

Erica C. Nakajima, MD, Analyzes Frontline Immune Checkpoint Inhibitors in KRAS+, PD-L1+ Non-Small Cell Lung Cancer
November 28, 2022

Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung cancer and PD-L1 expression.

Ursula A. Matulonis, MD, Talks Future of Mirvetuximab Soravtansine in Ovarian Cancer
November 27, 2022

Ursula A. Matulonis, MD, spoke about the next steps for mirvetuximab soravtansine in the treatment of patients with folate receptor α–high platinum-resistant ovarian cancer.

2022 ASTRO Round-Up: A Shift Toward a New Standard of Care in Radiotherapy and Reducing Cancer Treatment Duration
November 27, 2022

From shortening treatment duration without compromising efficacy in breast and prostate cancer to improving quality of life, experts share the main takeaways from the 2022 ASTRO Annual Meeting.

Durvalumab Plus Tremelimumab Appears Active in Advanced Sarcoma Subgroups
November 26, 2022

Results from a phase 2 trial indicated that subgroups of patients with advanced or metastatic sarcoma may benefit from durvalumab plus tremelimumab, with data encouraging further evaluation in the population.

Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPC
November 26, 2022

The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.

Sara Hurvitz, MD, Discusses The HER2-Low Breast Cancer Landscape Following 2022 ASCO, Cites Need for Future Investigation
November 25, 2022

According to Hurvitz, the findings of trials such as DESTINY-Breast04 and TROPiCS-02 shed light on potential new therapies for breast cancer, though more research is needed to address new agents and other unmet needs.

Unmet Needs and Future Directions in Multiple Myeloma Treatment
November 25, 2022

The panel closes their discussions by highlighting current unmet needs in multiple myeloma treatment and what excites them on the horizon.